Navigation Links
Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
Date:12/17/2013

CAMBRIDGE, Mass., Dec. 17, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Theo Melas-Kyriazi, CFO of Levitronix Technologies LLC and a director of Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has joined Moderna's board of directors.

Melas-Kyriazi brings extensive financial and executive leadership experience to Moderna, having previously served as CFO and vice president of corporate strategy for Thermo Electron Corporation (now Thermo Fisher Scientific). He also has experience as CEO of Thermo Spectra Corporation, a former subsidiary of Thermo Electron, and as a board member and investor in several early stage health sciences companies. Melas-Kyriazi joins Moderna's board as the company embarks on the next phase of its growth strategy focused on clinical development and building the world's leading mRNA platform.  

"I am thrilled that Theo is joining the Moderna board of directors. He brings important expertise and skill to the company as we scale up to build the leader in mRNA therapeutics," said Stephane Bancel, president and founding CEO of Moderna. "With his experience as CFO of Thermo Electron, a large, public life sciences company, and as a director of Valeant for the last ten years, during a period of extraordinary growth, he will be a tremendous asset to help guide Moderna's future growth."

"I am truly excited to be joining the board of Moderna, a company with tremendous potential to transform drug development," said Melas-Kyriazi. "Moderna's novel platform and ambitious vision stands out among early biotechnology leaders, and I look forward to helping the company deliver on its mission to improve the lives of patients across a broad range of diseases."

About Moderna Therapeutics

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.

For information contact:
Maria Favorito
617-761-6720
Maria.Favorito@fkhealth.com


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
2. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
3. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
4. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
5. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
6. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016 According to a new market ... (Polymer, Glass, Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, Environmental, ... global market is projected to reach USD 8.78 Billion by 2021 ... during the forecast period (2016 to 2021). ... ...
(Date:12/6/2016)... , Dec. 6, 2016  SRI International has ... million from the National Institutes of Health,s National ... Division of AIDS (NIAID-DAIDS) to support the manufacturing ... pre-exposure (PreP) agents. Under the seven-year contract, SRI ... development services for candidate HIV-prevention products that emerge ...
(Date:12/6/2016)... ... 2016 , ... RoviSys, a leading independent provider of comprehensive ... the opening of their new office building today. Located at 480 Green Oaks ... 200 employees focused on providing sales, engineering, and support services to customers in ...
(Date:12/5/2016)... Dec 5, 2016 Research and Markets ... - Technologies, Markets and Companies" to their offering. ... , , ... discovery using various -omics technologies such as proteomics and metabolomics. Molecular ... tests are also based on biomarker. Currently the most ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
Breaking Biology News(10 mins):